JP2015513549A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513549A5
JP2015513549A5 JP2014560104A JP2014560104A JP2015513549A5 JP 2015513549 A5 JP2015513549 A5 JP 2015513549A5 JP 2014560104 A JP2014560104 A JP 2014560104A JP 2014560104 A JP2014560104 A JP 2014560104A JP 2015513549 A5 JP2015513549 A5 JP 2015513549A5
Authority
JP
Japan
Prior art keywords
topical formulation
solution
alpha connexin
polypeptide
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560104A
Other languages
English (en)
Japanese (ja)
Other versions
JP6185937B2 (ja
JP2015513549A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028727 external-priority patent/WO2013131040A1/en
Publication of JP2015513549A publication Critical patent/JP2015513549A/ja
Publication of JP2015513549A5 publication Critical patent/JP2015513549A5/ja
Application granted granted Critical
Publication of JP6185937B2 publication Critical patent/JP6185937B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560104A 2012-03-01 2013-03-01 アルファコネキシンｃ末端（ａｃｔ）ペプチド含有局所用ゲル剤 Expired - Fee Related JP6185937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
US61/605,528 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (3)

Publication Number Publication Date
JP2015513549A JP2015513549A (ja) 2015-05-14
JP2015513549A5 true JP2015513549A5 (https=) 2016-04-07
JP6185937B2 JP6185937B2 (ja) 2017-08-23

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560104A Expired - Fee Related JP6185937B2 (ja) 2012-03-01 2013-03-01 アルファコネキシンｃ末端（ａｃｔ）ペプチド含有局所用ゲル剤

Country Status (17)

Country Link
US (5) US8846605B2 (https=)
EP (1) EP2819682B1 (https=)
JP (1) JP6185937B2 (https=)
KR (1) KR102038948B1 (https=)
CN (1) CN104271142B (https=)
AU (1) AU2013225716B2 (https=)
BR (1) BR112014021653B1 (https=)
CA (1) CA2866115C (https=)
DK (1) DK2819682T3 (https=)
IL (1) IL234380B (https=)
IN (1) IN2014DN07420A (https=)
MX (1) MX351881B (https=)
NZ (1) NZ629769A (https=)
RU (1) RU2657535C2 (https=)
SG (1) SG11201405359YA (https=)
WO (1) WO2013131040A1 (https=)
ZA (1) ZA201406373B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
SG10202107725RA (en) * 2017-02-16 2021-09-29 Firststring Research Inc Composition and methods for preventing radiation injury and promoting tissue regeneration
CN111182887A (zh) * 2017-06-14 2020-05-19 株式会社生物解决方案有限公司 用于改善皮肤皱纹或抗炎活性的包括物质p的化妆品组合物
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3849528A4 (en) * 2018-09-12 2023-07-26 Xequel Bio, Inc. NANOPARTICLE FORMULATIONS AND METHODS OF USE FOR ALPHA-CONNEXIN-C-TERMINAL PEPTIDES
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
AU2022267568A1 (en) * 2021-04-30 2023-11-16 Innovent Biologics (Suzhou) Co., Ltd. Oxm3 storage agent, oxm3 preparation, and preparation method
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
DK1146908T3 (da) 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
JP2002543825A (ja) 1999-05-14 2002-12-24 アーバー ビータ コーポレイション 造血細胞内分子相互作用
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2002042422A2 (en) 2000-11-10 2002-05-30 Arbor Vita Corporation Molecular interactions in hematopoietic cells
WO2002088370A2 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
WO2003032964A2 (en) 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7560430B2 (en) 2003-02-14 2009-07-14 Human Matrix Sciences, Llc Elastin digest compositions and methods utilizing same
CA3059497A1 (en) 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
SG158153A1 (en) 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
JP2008543877A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
EP1945307B1 (en) * 2005-10-11 2013-03-27 DPT Laboratories, LTD. Surfactant-free dispersions, compositions, and use in topical formulations
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
DK2166845T3 (en) 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
EP2245158A2 (en) 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
CA2710375A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
US20110243964A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
AU2008343839A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
AU2008343758A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
JP2011507599A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
JP2011507861A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
US20110144182A1 (en) 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides

Similar Documents

Publication Publication Date Title
JP2015513549A5 (https=)
RU2014139668A (ru) Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)
BR112016002939A2 (pt) composições farmacêuticas parenterais aquosas estáveis de peptídeos insulinotrópicos
JP2014515747A5 (https=)
CN103830720A (zh) 一种含缩宫素的药物组合物
HRP20240635T1 (hr) Dugodjelujući hormoni rasta i postupci proizvodnje istog
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
BR112019014876A2 (pt) composição líquida estável compreendendo toxina botulínica e método para estabilizar uma toxina botulínica
JP2008536483A5 (https=)
HRP20221355T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
JP2015508771A5 (https=)
Bao et al. Meprin A impairs epithelial barrier function, enhances monocyte migration, and cleaves the tight junction protein occludin
Dong et al. Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticles
AR079896A1 (es) Proceso para preparar composiciones farmaceuticas para la liberacion sostenida de analogos de somatostatina
CN105432598A (zh) 一种液基细胞保存液及其制备方法
JP2016523267A (ja) ヘプラペプチドの製剤
AR088727A1 (es) Peptidos ciclicos con actividad antineoplasica y antiangiogenica
CN104558150A (zh) 一类新型生长激素释放激素类似肽及其在制备治疗不孕不育药物中的应用
RU2016119565A (ru) Полипептиды длительного действия и способы их получения и введения
JP6125141B2 (ja) 点眼剤
JP2016535015A5 (https=)
BRPI0906045B1 (pt) Composição farmacêutica para administração nasal
CN101455647A (zh) 注射用甲磺酸加贝酯冻干制剂及制备方法
WO2020114328A1 (zh) 一种蓝铜肽整理剂及其制备方法
JP6179939B2 (ja) 高濃度γグロブリン製剤の粘度低下方法